These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 27622699)

  • 41. Fluticasone propionate in asthma: a long term dose comparison study.
    Verona E; Petrov D; Cserhati E; Hofman J; Geppe N; Medley H; Hughes S
    Arch Dis Child; 2003 Jun; 88(6):503-9. PubMed ID: 12765916
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy and safety of dry powder fluticasone propionate in children with persistent asthma.
    LaForce CF; Pearlman DS; Ruff ME; Silvers WS; Weinstein SW; Clements DS; Brown A; Duke S; Harding SM; House KW
    Ann Allergy Asthma Immunol; 2000 Nov; 85(5):407-15. PubMed ID: 11101186
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Fluticasone propionate hydrofluoroalkane inhalation aerosol in patients receiving inhaled corticosteroids.
    Lumry WR; Conway MM; LaForce CF; Pearlman DS; Scott CA; Herje NE; Wu WW; Crim C
    Ann Allergy Asthma Immunol; 2006 Jan; 96(1):51-9. PubMed ID: 16440533
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial.
    Lee LA; Bailes Z; Barnes N; Boulet LP; Edwards D; Fowler A; Hanania NA; Kerstjens HAM; Kerwin E; Nathan R; Oppenheimer J; Papi A; Pascoe S; Brusselle G; Peachey G; Sule N; Tabberer M; Pavord ID
    Lancet Respir Med; 2021 Jan; 9(1):69-84. PubMed ID: 32918892
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy and safety of fluticasone propionate 250 microg administered once daily in patients with persistent asthma treated with or without inhaled corticosteroids.
    Berger WE; Ford LB; Mahr T; Nathan RA; Crim C; Edwards L; Wightman DS; Lincourt WR; Rickard K
    Ann Allergy Asthma Immunol; 2002 Oct; 89(4):393-9. PubMed ID: 12392384
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Combined salmeterol 50 microg and fluticasone propionate 250 microg in the diskus device for the treatment of asthma.
    Shapiro G; Lumry W; Wolfe J; Given J; White MV; Woodring A; Baitinger L; House K; Prillaman B; Shah T
    Am J Respir Crit Care Med; 2000 Feb; 161(2 Pt 1):527-34. PubMed ID: 10673196
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Diskus and diskhaler: efficacy and safety of fluticasone propionate via two dry powder inhalers in subjects with mild-to-moderate persistent asthma.
    Galant SP; van Bavel J; Finn A; Gross G; Pleskow W; Brown A; Hamedani AG; Harding SM
    Ann Allergy Asthma Immunol; 1999 Mar; 82(3):273-80. PubMed ID: 10094218
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Randomized, double-blind trial evaluating the efficacy and safety of fluticasone propionate and fluticasone propionate/salmeterol delivered via multidose dry powder inhalers in patients with persistent asthma aged 12 years and older.
    Raphael G; Yiu G; Sakov A; Liu S; Caracta C
    J Asthma; 2018 Jun; 55(6):640-650. PubMed ID: 28763243
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Tolerability of a salmeterol xinafoate/fluticasone propionate hydrofluoroalkane metered-dose inhaler in adolescent and adult patients with persistent asthma: a 52-week, open-label, stratified, parallel-group, multicenter study.
    Cowie RL; Boulet LP; Keith PK; Scott-Wilson CA; House KW; Dorinsky PM
    Clin Ther; 2007 Jul; 29(7):1390-402. PubMed ID: 17825690
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy and safety of once-daily fluticasone furoate/vilanterol (FF/VI) versus twice-daily inhaled corticosteroids/long-acting β
    Devillier P; Humbert M; Boye A; Zachgo W; Jacques L; Nunn C; West S; Nicholls A; Antoun Z; Spinu L; Grouin JM
    Respir Med; 2018 Aug; 141():111-120. PubMed ID: 30053956
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of once- and twice-daily dosing of fluticasone propionate 200 micrograms per day administered by diskus device in patients with asthma treated with or without inhaled corticosteroids.
    Wolfe J; Rooklin A; Grady J; Munk ZM; Stevens A; Prillaman B; Duke S; Harding S
    J Allergy Clin Immunol; 2000 Jun; 105(6 Pt 1):1153-61. PubMed ID: 10856150
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Fluticasone alone or in combination with salmeterol vs triamcinolone in asthma.
    Baraniuk J; Murray JJ; Nathan RA; Berger WE; Johnson M; Edwards LD; Srebro S; Rickard KA
    Chest; 1999 Sep; 116(3):625-32. PubMed ID: 10492263
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The efficacy of once-daily fluticasone furoate/vilanterol in asthma is comparable with morning or evening dosing.
    Kempsford RD; Oliver A; Bal J; Tombs L; Quinn D
    Respir Med; 2013 Dec; 107(12):1873-80. PubMed ID: 24200619
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Fluticasone propionate powder administered through Diskhaler versus triamcinolone acetonide aerosol administered through metered-dose inhaler in patients with persistent asthma.
    Condemi JJ; Chervinsky P; Goldstein MF; Ford LB; Berger WE; Ayars GH; Rogenes PR; Edwards L; Pepsin PJ
    J Allergy Clin Immunol; 1997 Oct; 100(4):467-74. PubMed ID: 9338539
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of once- with twice-daily dosing of fluticasone propionate in mild and moderate asthma.
    Boulet LP; Cowie RL; Negro RD; Brett W; Gold M; Marques A; Thorburn WS; Stepner NM; Robson R
    Can Respir J; 2000; 7(3):239-47. PubMed ID: 10903487
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ethnic sensitivity assessment of fluticasone furoate/vilanterol in East Asian asthma patients from randomized double-blind multicentre Phase IIb/III trials.
    Gross AS; Goldfrad C; Hozawa S; James MH; Clifton CS; Sugiyama Y; Jacques L
    BMC Pulm Med; 2015 Dec; 15():165. PubMed ID: 26704701
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy and safety of once-daily, single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol in Japanese patients with inadequately controlled asthma: the CAPTAIN study.
    Nakamura Y; Hozawa S; Sagara H; Ohbayashi H; Lee LA; Crawford J; Tamaoki J; Nishi T; Fowler A
    Curr Med Res Opin; 2021 Sep; 37(9):1657-1665. PubMed ID: 34162298
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A randomized, double-blind, placebo-controlled, parallel-group study of once-daily inhaled fluticasone furoate on the hypothalamic-pituitary-adrenocortical axis of children with asthma.
    Bareille P; Tomkins S; Imber V; Tayob M; Dunn K; Mehta R; Khindri S
    Allergy Asthma Clin Immunol; 2020; 16():11. PubMed ID: 32042286
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Inhaled fluticasone propionate by diskus in the treatment of asthma: a comparison of the efficacy of the same nominal dose given either once or twice a day.
    Purucker ME; Rosebraugh CJ; Zhou F; Meyer RJ
    Chest; 2003 Oct; 124(4):1584-93. PubMed ID: 14555594
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Inhaled fluticasone propionate delivered by means of two different multidose powder inhalers is effective and safe in a large pediatric population with persistent asthma.
    Peden DB; Berger WE; Noonan MJ; Thomas MR; Hendricks VL; Hamedani AG; Mahajan P; House KW
    J Allergy Clin Immunol; 1998 Jul; 102(1):32-8. PubMed ID: 9679845
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.